It has been found that nuclear factor erythroid 2-related factor 2 (NRF2), which negatively regulates the NF-κB pathway by inhibiting nuclear translocation of NF-κB and blocking the degradation of IκB-α, may be a viable treatment target in slowing MASLD progression [188,189]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.